<DOC>
	<DOCNO>NCT02040831</DOCNO>
	<brief_summary>Respiratory syncytial virus ( RSV ) common cause illness infant child around world . This study evaluate safety immune response RSV vaccine RSV-seronegative infant child . This study companion study IMPAACT 2000 .</brief_summary>
	<brief_title>Safety Immune Response Live-Attenuated Respiratory Syncytial Virus ( RSV ) Vaccine RSV-Seronegative Infants Children</brief_title>
	<detailed_description>RSV common viral cause serious acute lower respiratory illness ( LRI ) infants child 5 year age world . RSV illness range mild upper respiratory tract illness ( URI ) severe LRI , include bronchiolitis pneumonia . Severe RSV disease infancy may also predispose child develop reactive airway disease childhood . The purpose study evaluate safety immunogenicity RSV vaccine ( RSV LID ΔM2-2 ) RSV-seronegative infant child least 6 month 24 month age . To determine study eligibility , screen process include blood collection . At study entry , eligible participant randomly assign receive one dose either RSV vaccine placebo , deliver nose drop . Participants also undergo review medical history , clinical assessment , nasal wash . They receive assign vaccine remain observation monitoring 30 minute receive vaccine . Additional study visit occur Days 3 , 5 , 7 , 10 , 12 , 14 , 17 , 19 , 21 , 28 , 56 . These visit include clinical assessment nasal wash ; Day 56 , blood collection also occur . On day study visit schedule ( Day 27 ) , participant ' parent guardian report participant ' temperature sign illness researcher e-mail phone . In October follow vaccination , participant may pre-RSV season blood collection visit . During RSV season , November March follow vaccination , researcher contact participant ' parent guardian weekly basis follow-up monitoring . During time frame , participant see medical provider fever , respiratory illness , otitis medium study visit , include nasal wash clinical assessment . In April follow vaccination , participant undergo final blood collection .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participant least 6 month le 25 month age time inoculation Parent guardian demonstrate understand study , sign inform consent , agree vaccine administration follow detailed explanation study Seronegative RSV antibody , define serum RSV neutralize antibody titer le 1:40 determine within 42 day prior inoculation Participant 's history review participant undergone physical examination indicate s/he good health . Permitted concomitant medication include nutritional supplement , medication gastroesophageal reflux , eye drop , topical medication , include topical steroid , topical antibiotic , topical antifungal agent . Participant receive routine immunization appropriate age , administer : 1. least 2 week prior study vaccine inoculation ( inactivated subunit vaccine rotavirus vaccine ) OR 2. least 4 week prior study vaccine inoculation ( live vaccine ) Participant expect available duration study Known suspect impairment immunological function , include maternal history positive HIV test Receipt immunosuppressive therapy include systemic corticosteroid within past 30 day . NOTE : Topical steroid , topical antibiotic , topical antifungal medication acceptable . Bone marrow/solid organ transplant recipient Major congenital malformation , include congenital cleft palate , cytogenetic abnormality , serious chronic disorder Previous immunization RSV vaccine Previous serious vaccineassociated AE anaphylactic reaction Known hypersensitivity vaccine component Lung heart disease , include wheeze event reactive airway disease . NOTE : Participants clinically insignificant cardiac abnormality require treatment may enrol . Participants one episode wheeze receive bronchodilator therapy single episode illness first year life additional wheezing episode bronchodilator therapy least 12 month may enrol . Member household contains immunocompromised individual Member household contain infant less 6 month age Attends day care infant less 6 month age , whose parent/guardian unable unwilling suspend daycare 14 day follow immunization . NOTE : Children attend facility separate child age minimize opportunity transmission virus direct physical aerosol contact acceptable . Temporary The following temporary selflimiting condition . Once resolve , participant may enrol , otherwise eligible , period temporary exclusion le 42 day screen . Otherwise , participant need rescreened . Participant rectal temperature great equal 100.4°F day plan vaccination , URI ( rhinorrhea , cough , pharyngitis ) nasal congestion significant enough interfere successful vaccination , otitis medium Participant receive kill vaccine live attenuate rotavirus vaccine within last 2 week , live vaccine within last 4 week , gamma globulin ( antibody product ) within past 3 month Receipt another investigational vaccine investigational drug within prior 28 day receive study inoculation Participant receive antibiotic systemic nasal steroid therapy acute illness within previous 3 day prior vaccination . NOTE : Permitted concomitant medication include nutritional supplement , medication gastroesophageal reflux , eye drop , topical medication , include ( limited ) topical steroid , topical antibiotic , topical antifungal agent . Participant receive salicylate ( aspirin ) salicylatecontaining product within past month Participant bear less 37 week gestation currently less 1 year age</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>